This is a global Phase III, open-label, randomized, controlled study designed to evaluate the efficacy, safety, and pharmacokinetics of adjuvant treatment with atezolizumab +T-AC compared with T-AC alone in patients with newly diagnosed triple-negative breast cancer who have had curativintent of their primary tumor and are candidates for adjuvant systemic therapy following surgery.

    Trial Coordinator
    Poonam Jani

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email:This email address is being protected from spambots. You need JavaScript enabled to view it.


    ETOP IBCSG Partners Foundation
    Coordinating Center, Bern, Switzerland
    Phone: +41 31 511 94 00
    Fax: +41 31 511 94 01
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


    Targeted Accrual
    2300

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login